Table 4.
The distribution of E. coli virulence factors among Tx patients with Cys and PN
| Cys (n = 110) | PN (n = 59) | Univariate Analysis |
Multivariate Analysis |
|||||
|---|---|---|---|---|---|---|---|---|
| OR | 95% CI | P | OR | 95% CI | P | |||
| Urovirulence genes of E. coli | ||||||||
| papC | 18 (16.5) | 14 (23.7) | 1.59 | 0.73 to 3.48 | 0.25 | |||
| papGII | 12 (11.0) | 14 (23.7) | 2.54 | 1.09 to 5.93 | 0.03 | |||
| papGIII | 15 (13.6) | 2 (3.4) | 4.50 | 0.99 to 20.38 | 0.05 | 5.07 | 1.07 to 24.13 | 0.041 |
| M-fimbriae | 5 (4.6) | 1 (1.7) | 0.36 | 0.04 to 3.17 | 0.36 | |||
| G-fimbriae | 2 (1.8) | 0 | 0.36 | 0.02 to 7.72 | 0.30 | |||
| aerobactin | 24 (21.8) | 14 (23.7) | 1.12 | 0.53 to 2.36 | 0.78 | |||
| Antibiotic resistance | ||||||||
| TMP/SMZ | 57 (51.8) | 30 (50.9) | 0.96 | 0.51 to 1.81 | 0.90 | |||
| nalidixic acid | 41 (37.3) | 12 (20.3) | 2.33 | 1.11 to 4.89 | 0.03 | |||
| pipemidic acid | 46 (41.8) | 13 (22.0) | 2.54 | 1.23 to 5.24 | 0.01 | 2.57 | 1.21 to 5.46 | 0.014 |
| ciprofloxacin | 37 (33.6) | 12 (20.3) | 0.50 | 0.24 to 1.05 | 0.07 | |||
| norfloxacin | 37 (33.6) | 12 (20.3) | 0.50 | 0.24 to 1.05 | 0.07 | |||
| ampicilin | 64 (58.2) | 33 (55.9) | 0.91 | 0.48 to 1.73 | 0.78 | |||
| cefalotin | 39 (35.4) | 21 (35.6) | 1.01 | 0.52 to 1.95 | 0.98 | |||
| ceftriaxone | 2 (1.8) | 1 (1.7) | 0.93 | 0.08 to 10.49 | 0.95 | |||
| gentamicin | 11 (10.0) | 4 (6.8) | 0.66 | 0.20 to 2.15 | 0.48 | |||
| nitrofurantoin | 0 | 0 | – | – | ||||
n (%), number (percentage) of patients.